Piper Sandler Reiterates Overweight Rating on Moderna (MRNA) Following FDA Approval of mRNA Flu Vaccine
Tweet Send to a Friend
Piper Sandler analyst Edward Tenthoff reiterated an Overweight rating and a $77.00 price target on Moderna (NASDAQ: MRNA) following the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
